India's pharma growth and investment fueled by government policies.
India’s Production Linked Incentive (PLI) scheme for the pharmaceutical sector has spurred substantial investment and production, according to recent reports. The scheme has driven ₹41,943 crore (approximately $5 billion) in investments, doubling its initial commitment.
The PLI scheme has also led to significant production increases, with cumulative sales reaching ₹3,35,036 crore from 1,988 products. Exports have accounted for ₹2,15,248 crore of these sales. The government initiative aims to boost domestic manufacturing and reduce reliance on imports, particularly for key pharmaceutical ingredients and products.
The scheme provides financial incentives to companies based on incremental sales, encouraging them to expand their manufacturing capabilities and invest in research and development. By incentivizing domestic production, the PLI scheme strengthens India’s position in the global pharmaceutical market. The increase in both investment and sales indicates a positive trajectory for the sector, driven by supportive government policies.
About the Author
